
  
    
      
        Background_NNP
        In_IN golden_JJ hamsters_NNS ,_, microinjections_NNS of_IN arginine_NN
        vasopressin_NN (_( AVP_NNP )_) into_IN the_DT anterior_NN hypothalamus_JJ trigger_NN
        grooming_VBG and_CC flank_NN marking_VBG ,_, a_DT stereotyped_JJ scent_NN marking_VBG
        behavior_NN [_NN 1_CD 2_CD ]_NN ._. Within_IN a_DT minute_NN after_IN AVP_NNP
        microinjections_NNS ,_, hamsters_NNS start_VBP to_TO lick_NN and_CC comb_NN sebaceous_JJ
        glands_NNS situated_VBN on_IN their_PRP$ dorsolateral_NN flanks_NNS ._. Bouts_NNP of_IN
        flank_NN gland_NN grooming_VBG may_MD be_VB so_RB intense_JJ that_IN the_DT flanks_NNS are_VBP
        left_VBN matted_JJ and_CC soaked_JJ in_IN saliva_NN ._. Flank_NNP marking_VBG behavior_NN is_VBZ
        observed_VBN soon_RB after_IN the_DT onset_NN of_IN grooming_VBG ,_, and_CC usually_RB
        within_IN two_CD minutes_NNS of_IN the_DT microinjection_NN ._. Flank_NNP marking_VBG is_VBZ
        a_DT scent_NN marking_VBG behavior_NN involved_VBN in_IN olfactory_NN
        communication_NN [_NN 3_CD ]_NN ,_, and_CC is_VBZ characterized_VBN by_IN arching_VBG the_DT
        back_NN and_CC rubbing_VBG the_DT flank_NN glands_NNS vigorously_RB against_IN
        objects_NNS in_IN the_DT environment_NN ._. The_DT concentrations_NNS of_IN AVP_NNP
        required_VBD to_TO induce_VB flank_NN marking_VBG are_VBP low_JJ (_( ranging_VBG from_IN 0_CD ._. 1_CD
        to_TO 100_CD μM_NN )_) [_NN 4_CD 5_CD ]_NN and_CC the_DT volumes_NNS microinjected_JJ in_IN the_DT
        anterior_NN hypothalamus_JJ are_VBP small_JJ (_( ranging_VBG from_IN 20_CD to_TO 100_CD
        nl_NN )_) ._. The_DT activation_NN of_IN flank_NN marking_VBG is_VBZ dose-dependent_JJ ,_, and_CC
        specific_JJ to_TO AVP_NNP ,_, as_IN microinjections_NNS of_IN other_JJ neuropeptides_NNS ,_,
        excitatory_NN amino_JJ acids_NNS ,_, and_CC catecholamines_NNS do_VBP not_RB elicit_NN
        the_DT behavior_NN [_NN 1_CD 2_CD 6_CD ]_NN ._. Flank_NNP marking_VBG is_VBZ also_RB specific_JJ to_TO
        AVP_NNP V_NNP 1_CD receptors_NNS ,_, as_IN the_DT behavior_NN is_VBZ selectively_RB inhibited_VBD
        by_IN V_NNP 1_CD receptor_NN antagonists_NNS and_CC activated_VBN by_IN V_NNP 1_CD receptor_NN
        agonists_NNS [_NN 4_CD 5_CD ]_NN ._.
        The_DT behavioral_JJ effects_NNS of_IN AVP_NNP are_VBP not_RB limited_VBN to_TO flank_NN
        marking_VBG in_IN hamsters_NNS ._. Vasopressin_NNP is_VBZ a_DT neurotransmitter_NN
        released_VBN centrally_RB to_TO affect_VB various_JJ behaviors_NNS ,_, e_SYM ._. g_SYM ._.
        arousal_NN [_NN 7_CD ]_NN ,_, temperature_NN regulation_NN [_NN 8_CD 9_CD ]_NN ,_, aggression_NN
        [_NN 10_CD 11_CD ]_NN ,_, memory_NN [_NN 12_CD ]_NN and_CC grooming_VBG [_NN 13_CD ]_NN ._. However_RB ,_,
        the_DT ability_NN of_IN centrally_RB acting_VBG AVP_NNP to_TO induce_VB intense_JJ
        stereotyped_JJ behaviors_NNS [_NN 1_CD 14_CD ]_NN raises_VBZ the_DT possibility_NN that_IN
        this_DT neuropeptide_NN may_MD be_VB associated_VBN with_IN the_DT induction_NN of_IN
        compulsive_JJ behaviors_NNS in_IN humans_NNS ._. Indeed_RB ,_, alterations_NNS in_IN AVP_NNP
        regulation_NN and_CC secretion_NN are_VBP thought_VBN to_TO be_VB one_CD possible_JJ
        biochemical_JJ abnormality_NN in_IN patients_NNS with_IN Obsessive_NNP
        Compulsive_NNP Disorder_NNP (_( OCD_NNP )_) [_NN 15_CD 16_CD 17_CD 18_CD ]_NN ._. This_DT disorder_NN
        is_VBZ characterized_VBN by_IN sudden_JJ ,_, recurrent_JJ thoughts_NNS or_CC images_NNS
        that_WDT intrude_VBP into_IN consciousness_NN (_( obsessions_NNS )_) driving_VBG
        stereotyped_JJ acts_NNS that_IN the_DT person_NN feels_VBZ compelled_VBN to_TO perform_VB
        (_( compulsions_NNS )_) [_NN 19_CD ]_NN ._. Interestingly_RB ,_, patients_NNS with_IN OCD_NNP
        show_NN elevated_VBD basal_NN levels_NNS of_IN AVP_NNP in_IN the_DT cerebrospinal_NN
        fluid_JJ and_CC exaggerated_JJ plasma_NN levels_NNS of_IN AVP_NNP in_IN response_NN to_TO
        hypertonic_JJ challenge_NN [_NN 16_CD ]_NN ._. Many_JJ patients_NNS with_IN anorexia_NN
        nervosa_NN and_CC bulimia_NN nervosa_NN ,_, both_DT compulsive_JJ eating_NN
        disorders_NNS ,_, have_VBP abnormal_JJ levels_NNS of_IN AVP_NNP in_IN the_DT cerebrospinal_NN
        fluid_NN and_CC plasma_NN [_NN 15_CD 17_CD ]_NN ._. Pediatric_NNP patients_NNS with_IN severe_JJ
        OCD_NNP have_VBP low_JJ levels_NNS of_IN AVP_NNP in_IN cerebrospinal_NN fluid_JJ ,_, while_IN a_DT
        subgroup_NN of_IN pediatric_JJ patients_NNS with_IN compulsive_JJ checking_NN
        rituals_NNS has_VBZ elevated_VBD AVP_NNP levels_NNS [_NN 18_CD ]_NN ._. Hence_RB ,_, there_EX are_VBP
        many_JJ clinical_JJ examples_NNS of_IN compulsive_JJ behavior_NN associated_VBN
        with_IN a_DT perturbation_NN in_IN the_DT AVP_NNP system_NN ._.
        Given_VBN the_DT association_NN between_IN AVP_NNP and_CC OCD_NNP and_CC the_DT
        stereotyped_JJ nature_NN of_IN AVP-induced_NNP flank_NN gland_NN grooming_VBG and_CC
        flank_NN marking_VBG ,_, the_DT present_JJ studies_NNS were_VBD undertaken_VBN to_TO
        determine_VB whether_IN clomipramine_NN and_CC fluoxetine_NN ,_, two_CD drugs_NNS
        used_VBN to_TO treat_VB OCD_NNP in_IN humans_NNS [_NN 20_CD ]_NN might_MD inhibit_VB these_DT
        AVP-induced_NNP behaviors_NNS ._. Clomipramine_NNP is_VBZ a_DT non-selective_JJ
        re-uptake_JJ inhibitor_NN of_IN serotonin_NN ,_, and_CC to_TO some_DT extent_NN
        norepinephrine_NN [_NN 21_CD ]_NN and_CC fluoxetine_NN is_VBZ a_DT selective_JJ
        serotonin_NN re-uptake_JJ inhibitor_NN [_NN 22_CD ]_NN ._. Both_DT of_IN these_DT drugs_NNS
        have_VBP proven_VBN to_TO be_VB effective_JJ in_IN different_JJ animals_NNS models_NNS of_IN
        OCD_NNP [_NN 23_CD ]_NN ._. As_IN an_DT additional_JJ control_NN ,_, hamsters_NNS were_VBD also_RB
        treated_VBN with_IN desipramine_NN ,_, a_DT noradrenergic_JJ re-uptake_JJ
        inhibitor_NN [_NN 24_CD ]_NN that_WDT has_VBZ been_VBN found_VBN ineffective_JJ in_IN
        inhibiting_VBG OCD_NNP in_IN preclinical_JJ [_NN 25_CD ]_NN and_CC clinical_JJ studies_NNS [_NN
        26_CD 27_CD ]_NN ._.
      
      
        Results_NNS
        Microinjection_NNP of_IN 10_CD μM_NN AVP_NNP caused_VBD robust_JJ grooming_VBG and_CC
        flank_NN marking_VBG ._. In_IN fact_NN ,_, animals_NNS groomed_JJ for_IN up_IN to_TO 50_CD %_NN of_IN
        the_DT duration_NN of_IN the_DT tests_NNS ._. The_DT comparisons_NNS between_IN groups_NNS
        showed_VBD some_DT effects_NNS of_IN treatment_NN on_IN flank_NN marking_VBG activity_NN
        (_( F_NN 
        (_( 3_CD ,_, 25_CD )_) =_SYM 3_CD ._. 6_CD ,_, p_NN <_NN 0_CD ._. 05_CD )_) (_( Fig_NNP ._. 1_LS )_) ._.
        Animals_NNS treated_VBN with_IN clomipramine_NN or_CC fluoxetine_NN flank_NN
        marked_VBD significantly_RB less_JJR than_IN vehicle-treated_JJ animals_NNS (_( p_NN
        <_NN 0_CD ._. 05_CD )_) ._. Animals_NNS treated_VBN with_IN desipramine_NN flank_NN marked_VBD
        as_RB much_RB as_IN vehicle-treated_JJ animals_NNS (_( p_NN >_NN 0_CD ._. 1_LS )_) ,_, but_CC flank_NN
        marked_VBD more_JJR than_IN animals_NNS treated_VBN with_IN clomipramine_NN (_( p_NN <_NN
        0_CD ._. 05_CD )_) ._. However_RB ,_, the_DT comparisons_NNS failed_VBD to_TO show_VB any_DT effect_NN
        of_IN treatment_NN on_IN grooming_VBG activity_NN (_( F_NN 
        (_( 3_CD ,_, 25_CD )_) =_SYM 0_CD ._. 61_CD ,_, p_NN >_NN 0_CD ._. 1_LS )_) (_( Fig_NNP ._. 1_LS )_) ._.
        Indeed_RB ,_, regardless_RB of_IN treatment_NN groups_NNS ,_, the_DT animals_NNS spent_VBD a_DT
        similar_JJ amount_NN of_IN time_NN grooming_VBG after_IN microinjection_NN of_IN
        AVP_NNP ._.
        Clomipramine_NNP caused_VBD a_DT significant_JJ (_( F_NN 
        (_( 2_CD ,_, 15_CD )_) =_SYM 124_CD p_NN <_NN 0_CD ._. 001_CD )_)
        dose-dependent_JJ reduction_NN in_IN flank_NN marking_VBG induced_VBN by_IN
        microinjection_NN of_IN 1_CD ._. 0_CD μM_NN AVP_NNP (_( Fig_NNP 2_LS )_) ._. Flank_NNP gland_NN grooming_VBG
        was_VBD unaffected_JJ by_IN drug_NN treatments_NNS (_( F_NN 
        (_( 2_CD ,_, 15_CD )_) =_SYM ._. 009_CD p_NN >_NN 0_CD ._. 9_CD )_)
      
      
        Discussion_NNP
        In_IN the_DT present_JJ experiments_NNS ,_, AVP-induced_NNP grooming_VBG and_CC
        flank_NN marking_VBG behaviors_NNS were_VBD tested_VBN in_IN hamsters_NNS exposed_VBN to_TO
        chronic_JJ treatment_NN with_IN psychotropic_JJ drugs_NNS shown_VBN in_IN
        preclinical_JJ and_CC clinical_JJ studies_NNS to_TO be_VB effective_JJ in_IN the_DT
        treatment_NN of_IN OCD_NNP [_NN 20_CD 28_CD ]_NN ._. The_DT results_NNS show_VBP differential_NN
        responsiveness_NNS to_TO these_DT treatments_NNS ._. While_IN grooming_VBG remained_VBN
        unaffected_JJ ,_, flank_NN marking_VBG was_VBD inhibited_VBD by_IN treatment_NN with_IN
        fluoxetine_NN and_CC clomipramine_NN but_CC not_RB desipramine_NN ._.
        Clomipramine_NNP showed_VBD a_DT dose-dependent_JJ decrease_NN in_IN flank_NN
        marking_VBG ._. These_DT observations_NNS lead_VBP to_TO two_CD main_JJ conclusions_NNS ._.
        The_DT first_JJ conclusion_NN is_VBZ related_VBN to_TO the_DT neurochemical_JJ
        properties_NNS of_IN fluoxetine_NN and_CC clomipramine_NN ._. As_IN noted_VBD
        earlier_RBR ,_, fluoxetine_NN is_VBZ a_DT selective_JJ serotonin_NN re-uptake_JJ
        inhibitor_NN while_IN clomipramine_NN is_VBZ a_DT non-selective_JJ re-uptake_JJ
        inhibitor_NN of_IN serotonin_NN ,_, and_CC to_TO some_DT extent_NN norepinephrine_NN ._.
        The_DT effectiveness_NN of_IN these_DT drugs_NNS presupposes_NNS a_DT serotonin_NN
        mechanism_NN is_VBZ involved_VBN in_IN the_DT suppression_NN of_IN AVP-induced_NNP
        flank_NN marking_VBG ._. The_DT second_JJ conclusion_NN is_VBZ related_VBN to_TO
        observations_NNS on_IN grooming_VBG ._. While_IN bouts_NNS of_IN grooming_VBG are_VBP
        coincident_JJ with_IN flank_NN marking_VBG ,_, the_DT selective_JJ inhibition_NN of_IN
        flank_NN marking_VBG and_CC not_RB grooming_VBG by_IN clomipramine_NN and_CC
        fluoxetine_NN suggest_VBP the_DT two_CD behaviors_NNS employ_VBP different_JJ
        neuronal_NN networks_NNS and_CC neurochemical_JJ signals_NNS for_IN their_PRP$
        control_NN ._. Although_IN earlier_JJR studies_NNS have_VBP implicated_VBN grooming_VBG
        behavior_NN as_IN a_DT phenomenological_JJ correspondent_NN to_TO OCD_NNP [_NN 25_CD 29_CD
        ]_NN inhibited_VBD by_IN drugs_NNS like_IN clomipramine_NN or_CC fluoxetine_NN ,_, the_DT
        situation_NN appears_VBZ different_JJ for_IN AVP-induced_NNP grooming_VBG in_IN
        hamsters_NNS ._. In_IN canine_JJ acral_NN lick_NN dermatitis_NNS ,_, the_DT excessive_JJ
        licking_VBG of_IN the_DT paws_NNS and_CC flanks_NNS was_VBD significantly_RB reduced_VBN by_IN
        fluoxetine_NN and_CC clomipramine_NN two_CD and_CC three_CD weeks_NNS into_IN
        treatment_NN ,_, respectively_RB [_NN 25_CD ]_NN ._. However_RB ,_, the_DT scale_NN of_IN the_DT
        reduction_NN was_VBD more_RBR pronounced_JJ over_IN a_DT five-week_JJ period_NN of_IN
        treatment_NN [_NN 25_CD ]_NN ._. Perhaps_RB flank_NN gland_NN grooming_VBG would_MD have_VB
        been_VBN significantly_RB altered_VBN in_IN these_DT studies_NNS if_IN drug_NN
        treatment_NN had_VBD been_VBN extended_VBN for_IN several_JJ more_JJR weeks_NNS ._.
        The_DT present_JJ data_NN show_VBP that_IN AVP-induced_NNP flank_NN marking_VBG is_VBZ
        selectively_RB inhibited_VBD by_IN chronic_JJ treatment_NN with_IN serotonin_NN
        re-uptake_JJ inhibitors_NNS such_JJ as_IN fluoxetine_NN or_CC clomipramine_NN ,_,
        instead_RB of_IN noradrenergic_JJ re-uptake_JJ inhibitors_NNS such_JJ as_IN
        desipramine_NN ._. Similar_JJ patterns_NNS of_IN results_NNS have_VBP been_VBN observed_VBN
        in_IN animal_NN models_NNS of_IN OCD_NNP such_JJ as_IN canine_JJ acral_NN lick_NN [_NN 25_CD ]_NN ._.
        These_DT observations_NNS are_VBP not_RB limited_VBN to_TO animal_NN models_NNS ._.
        Selective_NNP serotonin_NN re-uptake_JJ inhibitors_NNS are_VBP recognized_VBN as_IN
        an_DT effective_JJ biological_JJ treatment_NN for_IN OCD_NNP [_NN 20_CD ]_NN ._. In_IN a_DT
        double_JJ blind_JJ ,_, placebo_NN control_NN study_NN ,_, treating_VBG over_IN 500_CD
        patients_NNS with_IN OCD_NNP ,_, clomipramine_NN was_VBD found_VBN to_TO be_VB superior_JJ to_TO
        placebo_NN [_NN 30_CD ]_NN ._. Differences_NNS between_IN clomipramine_NN and_CC
        placebo_NN were_VBD noted_VBN as_RB early_RB as_IN one_CD week_NN after_IN the_DT start_NN of_IN
        treatment_NN ,_, with_IN significant_JJ clinical_JJ improvement_NN occurring_VBG
        after_IN six_CD weeks_NNS of_IN treatment_NN ._.
        Fluoxetine_NNP also_RB results_VBZ in_IN a_DT significant_JJ reduction_NN in_IN
        OCD_NNP severity_NN that_WDT takes_VBZ several_JJ weeks_NNS to_TO realize_VB [_NN 31_CD 32_CD ]_NN
        ._. This_DT therapeutic_JJ delay_NN has_VBZ been_VBN related_VBN to_TO a_DT
        down-regulation_JJ of_IN serotonin_NN autoreceptors_NNS with_IN chronic_JJ
        exposure_NN to_TO elevated_VBD serotonin_NN [_NN 33_CD 34_CD ]_NN ._. Together_RB ,_, these_DT
        data_NNS have_VBP been_VBN used_VBN to_TO link_VB OCD_NNP with_IN a_DT dysfunction_NN in_IN
        serotonin_NN neurotransmission_NN [_NN 35_CD ]_NN ._. Of_IN course_NN ,_, it_PRP is_VBZ
        unclear_JJ whether_IN prolonged_VBN treatment_NN with_IN these_DT re-uptake_JJ
        inhibitors_NNS is_VBZ restricted_VBN to_TO serotonin_NN alone_RB or_CC impact_NN on_IN
        the_DT activity_NN of_IN other_JJ neurotransmitter_NN systems_NNS ._. For_IN
        example_NN ,_, chronic_JJ treatment_NN with_IN fluoxetine_NN decreases_NNS the_DT
        release_NN of_IN AVP_NNP from_IN rat_NN hypothalamic_JJ organ_NN cultures_NNS [_NN 36_CD ]_NN
        ._. This_DT finding_NN is_VBZ particularly_RB noteworthy_JJ since_IN alterations_NNS
        in_IN AVP_NNP levels_NNS in_IN the_DT cerebrospinal_NN fluid_JJ have_VBP been_VBN
        correlated_JJ with_IN occurrences_NNS of_IN OCD_NNP [_NN 15_CD 16_CD ]_NN ._. The_DT
        occurrence_NN of_IN OCD_NNP has_VBZ also_RB been_VBN correlated_JJ with_IN increased_VBN
        levels_NNS of_IN oxytocin_NN ,_, a_DT neuropeptide_NN closely_RB related_VBD to_TO AVP_NNP [_NN
        37_CD ]_NN ._. In_IN golden_JJ hamsters_NNS ,_, the_DT elevation_NN of_IN serotonin_NN in_IN
        the_DT anterior_NN hypothalamus_JJ following_NN fluoxetine_NN treatment_NN
        can_MD inhibit_VB the_DT activity_NN of_IN the_DT AVP_NNP system_NN related_VBN to_TO
        aggressive_JJ behavior_NN [_NN 10_CD 11_CD ]_NN ._. The_DT ability_NN of_IN
        microinjected_JJ AVP_NNP in_IN the_DT anterior_NN hypothalamus_JJ to_TO enhance_VB
        aggressive_JJ behavior_NN in_IN golden_JJ hamsters_NNS is_VBZ blocked_VBN by_IN
        fluoxetine_NN treatment_NN and_CC serotonin_NN 5_CD HT_NNP 
        1_CD A_DT receptor_NN agonists_NNS [_NN 10_CD ]_NN ._. The_DT
        present_JJ data_NN include_VBP AVP-stimulated_NNP flank_NN marking_VBG in_IN the_DT
        list_NN of_IN behaviors_NNS suppressed_VBN by_IN fluoxetine_NN treatment_NN ._.
      
      
        Conclusion_NNP
        These_DT results_NNS show_VBP AVP-induced_NNP flank_NN marking_VBG is_VBZ
        inhibited_VBD by_IN chronic_JJ treatment_NN with_IN fluoxetine_NN or_CC
        clomipramine_NN ,_, but_CC not_RB desipramine_NN ._. This_DT pattern_NN of_IN
        responsiveness_NNS to_TO drug_NN treatment_NN suggests_VBZ that_IN AVP-induced_NNP
        flank_NN marking_VBG may_MD be_VB used_VBN as_IN a_DT model_NN for_IN screening_NN
        psychotropics_NNS used_VBN in_IN the_DT treatment_NN of_IN OCD_NNP ._. It_PRP is_VBZ a_DT
        cost-efficient_JJ ,_, ethical_JJ alternative_NN to_TO existing_VBG models_NNS ,_, and_CC
        can_MD be_VB useful_JJ in_IN further_JJ advancing_VBG our_PRP$ understanding_NN of_IN
        OCD_NNP ._. Future_JJ studies_NNS could_MD focus_VB on_IN effects_NNS of_IN long-term_JJ
        elevation_NN of_IN AVP_NNP in_IN hamsters_NNS ;_: dose-response_JJ manipulations_NNS
        of_IN psychotropics_NNS or_CC clinical_JJ use_NN of_IN AVP_NNP receptor_NN
        antagonists_NNS on_IN humans_NNS to_TO further_VB investigate_VB the_DT role_NN of_IN
        AVP_NNP in_IN OCD_NNP ._.
      
      
        Materials_NNS and_CC methods_NNS
        
          Animals_NNS and_CC Treatment_NNP
          Experiments_NNS were_VBD performed_VBN on_IN adult_NN male_JJ golden_JJ
          hamsters_NNS (_( 
          Mesocricetus_NNP auratus_JJ )_) weighing_VBG
          approximately_RB 160_CD g_SYM ._. The_DT animals_NNS underwent_VBD stereotaxic_JJ
          surgery_NN ,_, and_CC were_VBD allowed_VBN to_TO recover_VB before_IN behavioral_JJ
          testing_NN ._. The_DT hamsters_NNS were_VBD kept_VBN on_IN a_DT reverse_JJ light_JJ cycle_NN
          (_( 14_CD L_NNP :_: 10_CD D_NNP ,_, lights_NNS on_IN at_IN 19_CD :_: 00_CD )_) in_IN Plexiglas_NNP cages_NNS ,_, and_CC
          received_VBD food_NN and_CC water_NN 
          ad_NN libitum_NN ._. All_DT behavioral_JJ tests_NNS
          were_VBD performed_VBN during_IN the_DT dark_JJ phase_NN of_IN the_DT circadian_NN
          cycle_NN under_IN dim_NN red_JJ illumination_NN ._. All_DT animals_NNS were_VBD
          acquired_VBN and_CC cared_VBN for_IN in_IN accordance_NN with_IN the_DT guidelines_NNS
          published_VBN in_IN the_DT NIH_NNP Guide_NNP for_IN the_DT Care_NNP and_CC Use_NN of_IN
          Laboratory_NNP Animals_NNPS ._.
          Animals_NNS were_VBD divided_VBN into_IN four_CD treatment_NN groups_NNS :_:
          vehicle_NN control_NN (_( Veh_NNP ,_, 75_CD %_NN Tris-buffer_NNP saline_NN ,_, pH_NN 7_CD ._. 4_CD ,_, and_CC
          25_CD %_NN dimethyl_NN sulfoxide_NN ;_: n_NN =_SYM 9_CD )_) ,_, clomipramine_NN hydrochloride_NN
          (_( Clom_NNP ,_, 2_CD mg_NN /_NN day_NN ;_: n_NN =_SYM 8_CD )_) ,_, desipramine_NN hydrochloride_NN (_( Des_NNP ,_, 2_CD
          mg_NN /_NN day_NN ;_: n_NN =_SYM 9_CD )_) or_CC fluoxetine_NN hydrochloride_NN (_( Fluox_NNP ,_, 2_CD
          mg_NN /_NN day_NN ,_, n_NN =_SYM 8_CD )_) ._. Animals_NNS were_VBD given_VBN subcutaneous_JJ injections_NNS
          each_DT morning_NN for_IN two_CD consecutive_JJ weeks_NNS ._. The_DT doses_NNS and_CC
          treatment_NN regimen_NN for_IN each_DT drug_NN were_VBD comparable_JJ to_TO those_DT
          used_VBN in_IN several_JJ preclinical_JJ studies_NNS examining_VBG the_DT
          pharmacological_JJ control_NN of_IN OCD_NNP [_NN 25_CD 38_CD 39_CD ]_NN ._. Acute_NNP drug_NN
          trials_NNS were_VBD not_RB attempted_VBN as_IN the_DT experimental_JJ design_NN
          followed_VBN that_IN of_IN previously_RB published_VBN studies_NNS [_NN 25_CD 38_CD 39_CD
          ]_NN ._. After_IN 2_CD weeks_NNS of_IN treatment_NN ,_, hamsters_NNS were_VBD tested_VBN for_IN
          flank_NN marking_VBG after_IN a_DT microinjection_NN of_IN AVP_NNP (_( 10_CD μM_NN in_IN 100_CD
          nl_NN saline_NN )_) ._. This_DT dose_NN results_NNS in_IN a_DT maximal_NN activation_NN of_IN
          flank_NN marking_VBG [_NN 5_CD ]_NN ._. Vasopressin_NNP was_VBD microinjected_JJ into_IN
          the_DT anterior_NN hypothalamus_JJ of_IN the_DT hamsters_NNS with_IN a_DT 1_CD μl_NN
          Hamilton_NNP syringe_NN connected_VBN through_IN PE-_NNP 20_CD tubing_VBG to_TO a_DT
          33_CD -_: ga_NN needle_NN which_WDT was_VBD inserted_VBN in_IN the_DT guide_NN cannula_NN and_CC
          lowered_VBD to_TO the_DT target_NN site_NN ._. Vasopressin-triggered_NNP flank_NN
          marking_VBG occurs_VBZ with_IN 60_CD sec_NN of_IN microinjection_NN and_CC lasts_VBZ
          for_IN ca_MD ._. 4_CD -_: 5_CD min_NN [_NN 5_CD ]_NN ._. A_DT trained_VBN observer_NN recorded_VBD the_DT
          number_NN of_IN flank_NN marks_NNS and_CC the_DT amount_NN of_IN time_NN spent_VBD
          grooming_VBG for_IN a_DT 10_CD -_: minute_NN period_NN ._. All_DT behaviors_NNS were_VBD
          videotaped_JJ for_IN further_JJ verification_NN ._. Flank_NNP marking_VBG tests_NNS
          were_VBD run_VBN ca_MD ._. 60_CD -_: 90_CD min_NN after_IN subcutaneous_JJ drug_NN
          treatments_NNS ._. The_DT results_NNS were_VBD compared_VBN between_IN groups_NNS with_IN
          ANOVAs_NNP followed_VBN by_IN Fisher_NNP PLSD_NNP post-hoc_JJ tests_NNS ._.
          Although_IN the_DT effects_NNS of_IN fluoxetine_NN and_CC clomipramine_NN on_IN
          flank_NN marking_VBG were_VBD statistically_RB significant_JJ in_IN the_DT drug_NN
          comparison_NN studies_NNS (_( Fig_NNP 1_LS )_) ,_, the_DT effects_NNS were_VBD limited_VBN to_TO a_DT
          30_CD -_: 40_CD %_NN reduction_NN ._. As_IN noted_VBD ,_, the_DT microinjection_NN of_IN 10_CD μM_NN
          AVP_NNP causes_NNS maximal_NN flank_NN marking_VBG ,_, hence_RB it_PRP is_VBZ likely_JJ the_DT
          inhibition_NN of_IN behavior_NN with_IN drug_NN treatment_NN might_MD have_VB
          been_VBN more_RBR pronounced_JJ if_IN the_DT animals_NNS were_VBD challenged_VBN with_IN
          lower_JJR doses_NNS of_IN AVP_NNP ._. To_TO this_DT end_NN ,_, dose-response_JJ data_NNS for_IN
          clomipramine_NN were_VBD generated_VBN in_IN animals_NNS microinjected_JJ with_IN
          1_CD ._. 0_CD μM_NN AVP_NNP ._. Three_CD groups_NNS of_IN six_CD animals_NNS each_DT were_VBD treated_VBN
          with_IN vehicle_NN ,_, 0_CD ._. 001_CD mg_NN /_NN kg_NN or_CC 0_CD ._. 03_CD mg_NN /_NN kg_NN of_IN clomipramine_NN
          each_DT day_NN for_IN two_CD consecutive_JJ weeks_NNS ._. Since_IN the_DT initial_JJ
          drug_NN trials_NNS were_VBD effective_JJ with_IN fluoxetine_NN and_CC
          clomipramine_NN given_VBN in_IN a_DT dose_NN of_IN 2_CD mg_NN /_NN day_NN ,_, this_DT
          dose-response_JJ study_NN worked_VBD in_IN a_DT range_NN of_IN 100_CD -_: 10_CD ,_, 000_CD times_NNS
          less_JJR clomipramine_NN used_VBN in_IN the_DT initial_JJ trial_NN ._. On_IN the_DT day_NN
          of_IN testing_NN ,_, animals_NNS were_VBD treated_VBN with_IN clomipramine_NN and_CC
          60_CD -_: 90_CD min_NN later_RB microinjected_JJ with_IN 1_CD ._. 0_CD μM_NN AVP_NNP in_IN a_DT volume_NN
          of_IN 100_CD nl_NN and_CC scored_VBD for_IN flank_NN marking_VBG and_CC flank_NN gland_NN
          grooming_VBG ._.
        
        
          Stereotaxic_NNP Surgery_NNP /_NN Histology_NNP
          Stereotaxic_NNP surgery_NN was_VBD performed_VBN under_IN pentobarbital_NN
          (_( Nembutal_NNP ,_, 35_CD mg_NN /_NN kg_NN ,_, Abbott_NNP Laboratories_NNPS ,_, North_NNP Chicago_NNP ,_,
          I_PRP <_NN )_) anaesthesia_NN ._. The_DT Stereotaxic_NNP coordinates_VBZ were_VBD :_: 1_CD ._. 1_CD
          mm_NN anterior_NN to_TO the_DT bregma_NN ,_, 1_CD ._. 8_CD mm_NN lateral_NN to_TO the_DT
          midsagittal_NN suture_NN at_IN an_DT 8_CD °_NN angle_NN from_IN the_DT vertical_JJ line_NN ,_,
          and_CC 4_CD ._. 5_CD mm_NN below_IN the_DT dura_NN ._. A_DT unilateral_JJ 26_CD -_: gauge_VB guide_NN
          cannula_NN was_VBD lowered_VBN to_TO the_DT site_NN and_CC secured_VBN to_TO the_DT skull_NN
          with_IN dental_JJ cement_NN ._. The_DT guide_NN cannula_NN was_VBD closed_VBN with_IN a_DT
          33_CD -_: ga_NN obturator_NN extending_VBG 1_CD mm_NN beyond_IN the_DT guide_NN ._. The_DT
          inner-cannula_JJ used_VBN for_IN microinjections_NNS extended_VBD 3_CD ._. 0_CD mm_NN
          beyond_IN the_DT guide_NN to_TO reach_VB the_DT anterior_NN hypothalamus_JJ ._. At_IN
          the_DT end_NN of_IN the_DT study_NN ,_, animals_NNS were_VBD sacrificed_JJ by_IN
          decapitation_NN ,_, and_CC their_PRP$ brains_NNS were_VBD taken_VBN out_IN and_CC fixed_VBN
          in_IN 10_CD %_NN formalin_NN ._. Later_RB ,_, the_DT brains_NNS were_VBD sliced_JJ on_IN a_DT
          vibratome_NN and_CC the_DT sections_NNS were_VBD stained_JJ with_IN thionin_NN to_TO
          confirm_VB the_DT location_NN of_IN the_DT microinjection_NN sites_NNS in_IN the_DT
          anterior_NN hypothalamus_JJ ._.
        
      
    
  
